Beam Therapeutics CEO John M. Evans Reports Sale of $1.19 Million in Common Shares
Bitget2026/10/17 00:10- Beam Therapeutics CEO and director John M. Evans sold 50,000 common shares on October 15-16, 2026.
- Sales totaled 25,000 shares at $23.566 on October 15, with another 25,000 shares sold at $23.9838 on October 16.
- Evans exercised stock options for 25,000 common shares on each date at $1.03 per share.
- Direct common stock holdings stood at 1,047,205 shares following the transactions; indirect holdings totaled 103,000 shares through a trust.
- Remaining directly held stock options totaled 155,804, with an exercise price of $1.03.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
NEAR Protocol trading volume rose 66.8% to $10.41 billion in Q3 2026
Dow Jones Industrial Average rises on earnings, cheaper Crude Oil
Mining industry entering largest investment supercycle in history, Canada’s energy minister says
US artificial intelligence affairs chief: Recommendations for the responsible development of AI will be released soon
On Tuesday, Jay Clayton, Director of National Intelligence and Head of Artificial Intelligence Affairs in the United States, was asked during an interview when recommendations regarding AI would be made. He responded: "We will be rolling them out," but added that he could not commit to an exact date. On October 16, the newly established AI Special Task Force led by Jay Clayton under the Trump administration held its first meeting, with the task force officially operating for a term of 120 days.
Crypto prices
More
